1.19
+6.25%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Herantis Pharma Oyj
Its shares trade on Nasdaq Helsinki under the ticker HRTIS.HE. It has been listed since 11 June 2014. In the fiscal year to 31 December 2016, it reported revenue of €25,291 and a net loss of €4.4m. At that date it held total assets of €10.2m and shareholders' equity of €1.6m.
Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Jun 2014
- Website
- herantis.com ↗
Leadership
Pay as last reported
- Mr. Timo VeromaaIndependent Chairman of the Board
- Mr. Antti VuolantoChief Executive Officer, since 2022
- Mr. Frans WuiteIndependent Vice Chairman of the Board, since 2014
- Dr. Henri HuttunenChief Scientific Officer
- Dr. Arnab BhattacharjeeSenior Scientist
- Ms. Sigrid BoomsDirector of Clinical Development, since 2011
- Ms. Rebecka HolmnasProject Manager
- Ms. Katarina JaaskelainenProject Manager
- Mr. Jani KoskinenHead of Quality and CMC Development, since 2019
- Ms. Natalia KulesskayaSenior Scientist
- Ms. Outi LahdenperaChief Medical Officer
- Ms. Satu LeikasProject Manager
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Herantis Pharma Oyj focuses on regenerative biological therapies for Parkinson's disease and lymphatic diseases.
- CDNF biological therapy targets proteostatic mechanisms for neurodegenerative diseases treatment.
- Lymfactin VEGF-C gene therapy restores lymphatic structure for oncology related lymphedema.
Weaknesses
- Herantis Pharma Oyj has no commercialized products as of 2024.
- The company's pipeline relies on ongoing research for neurodegenerative disease treatments.
- Herantis lacks approved therapies for high impact diseases in the market.
Opportunities
- Herantis Pharma Oyj can expand its pipeline with new regenerative therapies for high impact diseases.
- The growing focus on neurodegenerative disease treatments offers market potential.
- Lymfactin VEGF-C gene therapy addresses unmet needs in oncology related lymphedema.
Threats
- Herantis Pharma Oyj faces competition from established pharmaceutical companies in neurodegenerative disease research.
- Regulatory approval delays could impact the development timeline for CDNF and Lymfactin therapies.
- The high cost of research and development may strain financial resources for the company.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.